Project Grant R03CA280302
Award Date
9/20/23
Completion Date
8/31/25
Dollars Obligated
$167K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $798,512 Project Grant was awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to Luminary Therapeutics, Inc., a small disadvantaged business located in Minnesota. The grant will fund the development of an allogeneic gamma/delta T-cell-based chimeric antigen receptor (CAR) therapy that targets two antigens, mesothelin and chondroitin sulfate proteoglycan-4, expressed in epithelial ovarian carcinoma. The therapy incorporates innovative...
The National Cancer Institute awarded Dartmouth College a $604,627 Project Grant under the Cancer Biology Research (CFDA 93.396) program to study ways to engineer durable antitumor protection using chimeric antigen receptor (CAR) T cell therapies. The project aims to deconvolve CAR T cell heterogeneity to understand how individual T cell subsets behave in vivo and identify engineering strategies to program CAR stem cell-like (TSCM) and tissue-resident memory (TRM) cell fates. This research could...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to advance the understanding of how a novel neoadjuvant therapy impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The $709,554 award to Emory University covers a 5-year period from April 1, 2025 to March 31, 2030. The key products and services to be delivered under this grant include: Gaining insights into how blocking the Semaphorin...
The National Cancer Institute (NCI) awarded Celdara Medical, LLC a $1,024,967 Project Grant (CFDA 93.395 - Cancer Treatment Research) to develop CM-HZ01, a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The project aims to advance CM-HZ01 to investigational new drug (IND) status as a best-in-class immunotherapy for patients with limited effective treatment options for this deadly form of skin cancer. The funding supports the research and development of CM-HZ01, an engineered...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $447,831 to the University of Colorado-Denver to develop chimeric antigen receptor (CAR) phagocytes as a novel treatment for glioblastoma, a highly aggressive type of brain cancer. The 5-year project aims to investigate the use of engineered immune cells to target and eliminate glioblastoma tumors, with a focus on pediatric high-grade gliomas. The research will explore the potential...
The National Cancer Institute (NCI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $652,725 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for treating glioblastoma, a deadly brain cancer. The funded project aims to test the safety and feasibility of injecting CAR T-cells engineered to secrete a T-cell engaging antibody (CARV3.TEAM-E...
The Project Grant award of $1,525,500.00 was provided by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The award, effective September 1, 2024 through August 31, 2027, supports research efforts by the New York University (NYU) School of Medicine to develop novel technologies for identifying tumor-specific antigens and engineering safer, more effective chimeric antigen receptor (CAR) T cell therapies. The work aims to...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $402,600 to the Sloan-Kettering Institute for Cancer Research in New York to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The key objectives are to (1) evaluate the efficacy and safety of U5 snRNP200-targeted CAR T cells,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $1,013,623 to March Biosciences Inc. to develop and test dual-targeting chimeric antigen receptor (CAR) T-cell therapies for treating T-cell acute lymphoblastic leukemia and T-cell lymphoma. The project aims to create allogeneic (partially-matched donor-derived) CAR T-cells targeting the CD5 and CD7 antigens, which are expressed on the majority of T-cell malignancies. The goal is to...
The National Cancer Institute (NCI) awarded a $218,089 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel Chimeric Antigen Receptor Macrophage (CAR-M) immunotherapy for the treatment of triple-negative breast cancer (TNBC). The key products or services to be delivered under this 2-year award include: 1) Evaluating the specificity, efficacy, and impact on angiogenesis of an anti-CSPG4...